Format

Send to

Choose Destination
Can J Gastroenterol Hepatol. 2016;2016:7603526. Epub 2016 Oct 24.

The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet-Remaining Challenges in Hepatitis C.

Author information

1
Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
2
Centre de Recherche du Centre Hospitalier Universitaire de Montréal (CHUM), Montreal, QC, Canada.
3
The Kirby Institute, UNSW, Sydney, NSW 2052, Australia.
4
Simon Fraser University, Burnaby, BC, Canada.
5
British Columbia Centre for Disease Control, Vancouver, BC, Canada V5Z 4R4; University of British Columbia, Vancouver, BC, Canada V6T 1Z4.
6
Multi-Organ Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.
7
Chronic Viral Illnesses Service, Division of Infectious Diseases and Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
8
Department of Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK, Canada.
9
Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada H3A 2B4.

Abstract

Hepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a priority and supported the establishment of a National Hepatitis C Research Network. In 2015, the introduction of new interferon- (IFN-) free therapies with high cure rates (>90%) and few side effects revolutionized HCV therapy. However, a considerable proportion of the population remains undiagnosed and treatment uptake remains low in Canada due to financial, geographical, cultural, and social barriers. Comprehensive prevention strategies, including enhanced harm reduction, broader screening, widespread treatment, and vaccine development, are far from being realized. The theme of the 2016 symposium, "We're not done yet: remaining challenges in Hepatitis C," was focused on identifying strategies to enhance prevention, diagnosis, and treatment of HCV to reduce disease burden and ultimately eliminate HCV in Canada.

PMID:
27843889
PMCID:
PMC5098058
DOI:
10.1155/2016/7603526
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center